Compare FAF & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FAF | LNTH |
|---|---|---|
| Founded | 1889 | 1956 |
| Country | United States | United States |
| Employees | N/A | 1193 |
| Industry | Specialty Insurers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.6B |
| IPO Year | 2009 | 2014 |
| Metric | FAF | LNTH |
|---|---|---|
| Price | $72.75 | $100.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $82.50 | ★ $87.00 |
| AVG Volume (30 Days) | 593.5K | ★ 1.2M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | ★ 376.19 | N/A |
| EPS | ★ 3.33 | 2.91 |
| Revenue | ★ $7,452,200,000.00 | $343,374,000.00 |
| Revenue This Year | $7.85 | N/A |
| Revenue Next Year | $5.57 | $14.19 |
| P/E Ratio | ★ $21.85 | $34.70 |
| Revenue Growth | ★ 21.61 | 3.62 |
| 52 Week Low | $56.20 | $49.67 |
| 52 Week High | $79.87 | $111.86 |
| Indicator | FAF | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 62.57 | 47.12 |
| Support Level | $64.47 | $100.51 |
| Resistance Level | $79.87 | $102.66 |
| Average True Range (ATR) | 1.44 | 0.54 |
| MACD | 0.16 | 0.16 |
| Stochastic Oscillator | 92.11 | 60.62 |
First American Financial Corp is engaged in the business of providing title insurance, settlement services, and other financial services and risk solutions. The group's reportable segments are: Title insurance and services, Home warranty, and Corporate. Maximum revenue is generated from the Title insurance and services segment, which provides title insurance, closing, escrow, and related services domestically and internationally in connection with residential and commercial real estate transactions. This segment also provides solutions to mitigate risk and facilitate real estate transactions, along with offering banking, trust, warehouse lending, mortgage subservicing and wealth management services. The majority of the group's revenue is generated from escrow fees and insurance premiums.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.